Wanbury Limited has announced a significant expansion of its product portfolio with the launch of four new anesthetic Active Pharmaceutical Ingredients (APIs) at its Tanuku facility. This strategic move represents a major step forward in the company's pharmaceutical manufacturing capabilities and market presence.

Product Launch Details

The company has successfully launched four new anesthetic APIs at its Tanuku manufacturing facility. This expansion demonstrates Wanbury's commitment to strengthening its position in the specialized pharmaceutical ingredients market.

Revenue Projections and Business Impact

The launch of these new anesthetic APIs is expected to generate substantial revenue for Wanbury Limited. The company has set an ambitious target of ₹100 crore in revenue from these products by FY 2026-27. This revenue projection indicates the company's confidence in market demand and its manufacturing capabilities.

The new product line is anticipated to add 15% to the company's annual revenue, highlighting the significant contribution these anesthetic APIs will make to Wanbury's overall financial performance. This expansion aligns with the company's growth strategy in the pharmaceutical sector.

Strategic Significance

The introduction of anesthetic APIs represents Wanbury's strategic focus on specialized pharmaceutical ingredients. By expanding into the anesthetic segment, the company is diversifying its product portfolio and potentially reducing dependence on existing product lines. The Tanuku facility's role in this expansion underscores the importance of this manufacturing location in the company's operational framework.

Wanbury Limited has announced key board decisions regarding the re-appointment of its Independent Director and scheduling of an Extraordinary General Meeting. The pharmaceutical company's board meeting held on December 10, 2025, addressed important governance matters requiring shareholder approval.

Board Approves Director Re-appointment

The Board of Directors approved the re-appointment of Mr. Manojkumar Khubchand Gursahani (DIN: 01064558) as Non-Executive Independent Director. His current tenure is set to end on January 7, 2026, and the proposed re-appointment will be effective from January 8, 2026, to January 7, 2027.

Mr. Gursahani has confirmed that he continues to meet the criteria of independence under the provisions of the Companies Act, 2013, and the SEBI Listing Regulations.

Extraordinary General Meeting Scheduled

The board has approved the issuance of notice for convening an Extraordinary General Meeting (EGM) of shareholders. The meeting is scheduled for Monday, January 5, 2026, to seek necessary approval from shareholders for the re-appointment through a special resolution.

Director Profile and Experience

Mr. Manojkumar Khubchand Gursahani brings over 30 years of professional experience to the board. He is a distinguished thought leader holding a graduate degree from Mumbai University and serves as a TED speaker, global strategist, and author of "The Human Connect."

His professional accomplishments include:

• Co-founder of Vera Healthcare Technologies, an AI-driven platform for early detection of ocular diseases
• Executive Director at the Global Chamber
• Mumbai Chair for the Las Vegas Chamber of Commerce
• Managing Trustee of the Indian Relief Foundation
• Advisor to Lion Tarachand Bapa Hospital
• Immediate Past President of the Rotary Club of Queens Necklace, Mumbai

Compliance and Independence

The company has confirmed that Mr. Gursahani is not related to any of the directors of the company and is not debarred from holding the office of director by virtue of any order of SEBI or any other authority. This ensures compliance with regulatory requirements for independent directors.

Meeting Details

The board meeting commenced at 4:30 PM and concluded at 5:15 PM on December 10, 2025. The company has informed both BSE Limited and National Stock Exchange of India about these decisions in accordance with Regulation 30 of the SEBI Listing Regulations.